Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Umbilical Cord Blood Transplant with Myeloablative Conditioning
NCT00719888Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Nov 2005
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of thiotepa in Acute Biphenotypic Leukemia (BAL), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and 15 more (2 arms), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Overall Survival at 1 year. Started Nov 2005; status: completed.
02
Drugs
thiotepa
03
Conditions
Acute Biphenotypic Leukemia (BAL)acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)Burkitt lymphoma (BL)chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00719888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00719888.